$7.26
3.07% day before yesterday
Nasdaq, Jul 11, 10:02 pm CET
ISIN
US64049M2098
Symbol
NEO

NeoGenomics, Inc. Stock price

$7.26
-0.57 7.28% 1M
-5.37 42.52% 6M
-9.22 55.95% YTD
-7.09 49.41% 1Y
-1.25 14.69% 3Y
-27.73 79.25% 5Y
+0.83 12.91% 10Y
+6.91 1,974.29% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.23 3.07%
ISIN
US64049M2098
Symbol
NEO
Sector

Key metrics

Basic
Market capitalization
$934.3m
Enterprise Value
$1.1b
Net debt
$183.8m
Cash
$358.1m
Shares outstanding
128.4m
Valuation (TTM | estimate)
P/E
negative | 45.3
P/S
1.4 | 1.2
EV/Sales
1.7 | 1.5
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
55.1%
Return on Equity
-8.7%
ROCE
-6.4%
ROIC
-6.9%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$672.4m | $752.9m
EBITDA
$-71.3m | $55.9m
EBIT
$-85.1m | $-77.8m
Net Income
$-77.6m | $20.6m
Free Cash Flow
$-32.4m
Growth (TTM | estimate)
Revenue
10.1% | 14.0%
EBITDA
10.3% | 212.7%
EBIT
9.9% | 8.9%
Net Income
7.8% | 126.1%
Free Cash Flow
18.2%
Margin (TTM | estimate)
Gross
44.3%
EBITDA
-10.6% | 7.4%
EBIT
-12.7%
Net
-11.5% | 2.7%
Free Cash Flow
-4.8%
More
EPS
$-0.6
FCF per Share
$-0.3
Short interest
4.6%
Employees
2k
Rev per Employee
$300.0k
Show more

Is NeoGenomics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

NeoGenomics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a NeoGenomics, Inc. forecast:

11x Buy
58%
8x Hold
42%

Analyst Opinions

19 Analysts have issued a NeoGenomics, Inc. forecast:

Buy
58%
Hold
42%

Financial data from NeoGenomics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
672 672
10% 10%
100%
- Direct Costs 374 374
5% 5%
56%
298 298
17% 17%
44%
- Selling and Administrative Expenses 335 335
9% 9%
50%
- Research and Development Expense 34 34
22% 22%
5%
-71 -71
10% 10%
-11%
- Depreciation and Amortization 14 14
8% 8%
2%
EBIT (Operating Income) EBIT -85 -85
10% 10%
-13%
Net Profit -78 -78
8% 8%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about NeoGenomics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeoGenomics, Inc. Stock News

Neutral
Business Wire
12 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
Neutral
Business Wire
13 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.
Neutral
Business Wire
19 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.
More NeoGenomics, Inc. News

Company Profile

NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Head office United States
CEO Anthony Zook
Employees 2,200
Founded 1998
Website neogenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today